tradingkey.logo

Eton Pharmaceuticals Inc

ETON
查看詳細走勢圖
16.830USD
-0.160-0.94%
收盤 12/26, 16:00美東報價延遲15分鐘
451.34M總市值
虧損本益比TTM

Eton Pharmaceuticals Inc

16.830
-0.160-0.94%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.94%

5天

+2.81%

1月

+3.95%

6月

+20.13%

今年開始到現在

+26.35%

1年

+28.97%

查看詳細走勢圖

TradingKey Eton Pharmaceuticals Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

Eton Pharmaceuticals Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在藥品行業排名49/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價30.00。中期看,股價處於下降通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Eton Pharmaceuticals Inc評分

相關信息

行業排名
49 / 158
全市場排名
126 / 4563
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 3 分析師
買入
評級
30.000
目標均價
+83.37%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Eton Pharmaceuticals Inc亮點

亮點風險
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
業績高增長
公司營業收入穩步增長,連續3年增長83.57%
業績增長期
公司處於發展階段,最新年度總收入39.01M美元
估值合理
公司最新PE估值-67.60,處於3年歷史合理位
機構減倉
最新機構持股16.82M股,環比減少0.00%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉1.34M股
活躍度降低
近期活躍度降低,過去20天平均換手率0.64

Eton Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Eton Pharmaceuticals Inc簡介

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
公司代碼ETON
公司Eton Pharmaceuticals Inc
CEOBrynjelsen (Sean E)
網址https://etonpharma.com/

常見問題

Eton Pharmaceuticals Inc(ETON)的當前股價是多少?

Eton Pharmaceuticals Inc(ETON)的當前股價是 16.830。

Eton Pharmaceuticals Inc 的股票代碼是什麼?

Eton Pharmaceuticals Inc的股票代碼是ETON。

Eton Pharmaceuticals Inc股票的52週最高點是多少?

Eton Pharmaceuticals Inc股票的52週最高點是23.000。

Eton Pharmaceuticals Inc股票的52週最低點是多少?

Eton Pharmaceuticals Inc股票的52週最低點是11.087。

Eton Pharmaceuticals Inc的市值是多少?

Eton Pharmaceuticals Inc的市值是451.34M。

Eton Pharmaceuticals Inc的淨利潤是多少?

Eton Pharmaceuticals Inc的淨利潤為-3.82M。

現在Eton Pharmaceuticals Inc(ETON)的股票是買入、持有還是賣出?

根據分析師評級,Eton Pharmaceuticals Inc(ETON)的總體評級為買入,目標價格為30.000。

Eton Pharmaceuticals Inc(ETON)股票的每股收益(EPS TTM)是多少

Eton Pharmaceuticals Inc(ETON)股票的每股收益(EPS TTM)是-0.249。
KeyAI